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1083-143 Does Pretreatment With Statins Before Percutaneus 
Coronary Intervention Reduce Myonecrosis? 
Su Min Chanq, Naji Yazbek, John A. Farmer, Nasser Lakkis, Baylor College of Medicine, 
Houston, TX 
Background: Cardiac enzyme elevation peri PCI carnes a worse outcome. Objective 
Determine if pretreatment with statins prior to PCI reduces enzyme elevation periPCl and 
other cardiac events (CE). Methods: 119 consecutive pts ( 63 on statins prior to PCI , 56 
not )underwent PCI were followed for 6 months. We compared the peri PCI cardiac 
enzyme elevation above 3 times normal and 6 months CE rate (death, peri PCI myocar- 
dial infarctlon (Ml), non fatal MI, target vessels revasculanzation (TVR) and unstable 
angina requiring hospitalization) Of not pretreated pts ,72% were on statins at follow up 
as compared to 98 % of pretreated pts. Results: Pretreated Patlents had more history of 
Ml or revascularization (63% vs 43%, p=O.O15), hyperllpidemia (60% vs 48% p=O.OOl), 
hypertension (83% vs 49% p=O.OZ) .The rest of baseline characteristics were similar 
including use of glycoprotein Ilb/llla inhibitors (60% vs 68% p=NS) and type of lesions. 
Pretreatment with statins had less periprocedure enzyme elevation (2% vs IO % p= 0.04) 
and lower CE rate at 6 months (21% vs 41% p=O.O15). After adjusting for 15 baseline 
characteristics, use of StatIns prior to PCI was associated with a decrease in the risk of 
enzyme elevation and CE. (OR 0.2, Cl 0.06-0.63, p=O.O06). Age > 65 years and type b2/ 
C lesions predicted worse outcome. Conclusion: Statins therapy prior to PCI may 
reduce periprocedure cardiac enzyme elevation and subsequent cardiac events. These 
results need to be confirmed in prospective randomized trials. 
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1083-144 Statins Potentiate the Anticoagulant Effects of Low 
Molecular Weight Heparin 
Sirisha Puppala, Katherine Zamecki, Jennifer Zimmer, Rohit R. Arora, Biren Bhatt, Jesse 
Houghton, Mir Chowdhury, Charles R. Spillert. New Jersey Medical School, Newark, NJ 
Background: Pravastatin sodium (PS) has been shown to have an anticoagulant effect in 
patrents. We have shown that PS has anticoagulant effects which are unrelated to a tis- 
sue factor pathway. Whether PS can potentlate the anticoagulant effects of low molecu- 
lar weight heparln (LMWH, Dalteparin) IS discussed. 
Methods: One milliliter of titrated whole blood (CWB) was incubated for 10 minutes at 37 
degrees with the following: 20 ~1 water (control); 16 Kg/ml PS; 0.25 U/ml LMWH; 16 pgl 
ml PS and 0.25 U/ml LMWH combined. The clotting time (set) was determined on a Son- 
oclot Coagulation Analyzer, a miniviscometer, which is sensitive to early fibrin polymer 
generation. 
Results: The clotting times are as follows: control 355 f 74; PS 462 * 75; 
LMWH 636 * 191 and PS + LMWH 610 * 119. All values were significantly different from 
each other (~‘0.05 or less). 
Conclusion: PS prolongs clotting time as does LMWH when compared to the control. In 
addition. the combination of PS and LMWH prolongs clotting time when compared to 
either alone. The enhanced anticoagulant effects of this combination of drugs may also 
cxcur when used clinically. A rapid clinical blood clotting assay capable of monitoring 
these apparently beneficial effects would be an asset. 
1083-145 Variability in the ASCAl Gene but Not HMG-CoA 
Reductase Predicts Low-Density Lipoprotein Lowering 
Effects of Statins 
Gualberto Ruano. Chad Messer, Bradley Dain, Richard Judson. Carol Reed, Antonio 
Gotto. Genaissance Pharmaceuticals, New Haven, CT, Weill Cornell Medical College, 
New York, NY 
Background: ABCAI (ATP-binding cassette, sub-family A_ABCl_, member 1) is 
involved in Tangier disease and is known to play a role in cholesterol homeostasis but 
not in statin treatment. HMGCR (HMGCoA reductase) is the target for statins. We inves- 
tigated whether variability in these genes may be wolved in statin response using the 
STRENGTH study, &htin fisponse &am&d by @?ne+c &plotype Markers, a phar- 
macogenetic study of statin efficacy). 
Methods 425 patients with hyperlipidemla were randomly assigned to 6 weeks of treat- 
ment with one of three statins: 8Omg/day simvastatin (N=l48), EOmgiday atowastatin 
(N=l39) or 40mg/day pravastatin (N=l38). We sequenced the ABCAl and HMGCA 
genes in 679 hyperlipidemlc patients plus 93 other individuals. We constructed haplotype 
markers from unphased genotypes (Drysdale, et al, PNAS, 97:19, 2000). Each marker 
was tested for an associarion with LDL reduction using ANCOVA models. Permutation 
tests were used to adjust for the multiple markers considered. 
Results: We discovered 179 SNPs Including 30 novel, non-synomymous SNPs in 
ABCA1. We found a significant association between an ABCAl haplotype marker and 
LDL reduction by statin treatment (P~O.0001) The association is also seen in the Individ- 
ual statin groups with p-values ranging from 0.04 to 0.003. The marker Includes 
GLU(1192) ASP plus 4 other SNPs. Patients with tl copy of the marker respond wth 
10% less LDL reduction than those without the marker. There were no differences in 
basellne lipids or HDL response between individuals based on this marker. 
For HMGCR, sequencing in our cohort revealed 51 SNPs. We detected no association 
between haplotype markers of HMGCR and statln response. 
Conclusion: Genes involved in cholesterol and lipid metabolic dwases should be can- 
dldates for pharmacogenetic analysis of drug response. Drug targets. although useful for 
drug screening, may not influence interindiwdual differences in drug response. 
ORAL CONTRIBUTIONS 
804 Genetic Determinants of Atherosclerosis 
Monday, March 31, 2003, 9:15 a.m.-10:30 a.m. 
McCormick Place, Room S103 
9:15 a.m. 
804-l LOX-l Polymorphism as a Susceptibility Genetic Marker 
for Atherosclerosis 
Ruaaiero Manaq Fabrizio Clementi, Gianmarco Contino, Giovanni B. Forleo. Paola 
Borgiani, Annalisa Botta, Annamaria Nardone, Gaetano Chiricolo, Massimo Marchei, 
Alessia Romeo, Sabina Guarino, Clarissa Cola, Maria Rosaria D’Apice, Masslmo 
Federici, lbrahim Fahdi, Renato Laura, Francesco Romeo, Giuseppe Novelli. Jawahar L. 
Mehta, University of Tor Vergata, Rome, Italy, University of Arkansas for Medical 
Sciences, Little Rock, AR 
Background and Objectives: Atherosclerosis is the principal process contributing to the 
pathogenesis of coronary artery disease (CAD), cerebral infarctlon. and penpheral vas- 
cular disease. A large number of risk factors such as hypertension. hypercholester- 
olemia, diabetes, obesity, smoking and shear stress leads to endothelial activation and/ 
or dysfunction, which elicit a series of cellular interactions that culminate in atherogene- 
sis. Several biochemical and functional studies suggest that a lectm-like receptor for oxi- 
dized low-density-lipoprotein (ox-DL), termed LOX-l. may be involved in atherogenesis. 
A recent linkage study performed in a mouse model, identified LOX-l as candidate sus- 
ceptibility gene for human atherosclerosis. Aim of this study is to investigate the role of 
the LOX-1 gene in human atherosclerosis susceptibility through association studies in 
different populations. 
Mated&and Methods: We screened a group of 164 Italian individuals with angiographlc 
CAD phenotype (CAD; n=66) or without any angiographically demonstrable disease 
(CAD-free; w76) and a group of 35 individuals from Arkansas (CAD, n=14; CAD-free, 
n=21). 
Results: We charaderized five dtfferent SNPs (SNP l-5) at the LOX-l locus I” these 
populations. We demonstrated that SNP4 (A to G transltion) correlates with CAD with a 
high degree of specificity in the Italian population (X’ = 7,37: P. 0.007; ldf) and repro- 
duced this association also in the American group (X*=5.1 I; P. 0.0237; ldf). 
Conclus;on:On the basis of these data on the prevalence of LOX-l SNPs in two different 
angiographically documented CAD populations, we think that LOX-l may be a potent 
candidate gene for atherogenesls and endothelial dysfunction in response to ox-LDL. 
Work supported by the Italian Ministry of Universrty and Research (MIUR) 
9:30 a.m. 
804-2 Genetic Determinants of Nicotine-Induced 
Angiogenesis 
Edwin Chanq, Yan Wang, Hanh M. Bui. Johannes Jacobi, Christopher Heeschen, James 
J. Jang, John P. Cooke, Stanford University Medical School, Stanford, CA 
Background: Nicotine is a potent angiogenic agent which Induces tumor angiogenesis 
and plaque neovascularizatlon. The angiogenic effect of nicotine occurs at concentra- 
tions similar to those found in plasma of moderate smokers. Nlcotlne action is medlated 
by endothelial nicotlnic cholinergic receptors (nAChR). We hypothesize that stimulation 
of the nAChR activates signal transduction pathways and transcriptional pathways that 
an? distinct from other anglogenic factors. Methods: We identified nicotine-regulated 
genes by using subtraction hybndization technology to isolate the differentrally expressed 
genes. We also employed high-throughput microarray transcriptional profiling to examine 
and validate gene expression profiles. Human micro vascular endothelial cells were 
treated with vehicle or nicotine (IO-‘M), and were subjected to PCR-selected subtraction 
hybridization. Results: Nicotine increased proliferative but decreased apoptotlc indices in 
sub confluent proliferatmg endothelial cells (HUVEC and HCAECs) with respect to 
untreated cells. Hexamethonium blocked the anti-apoptotic effect of nicotine. In nicotine 
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treated cells, a number of differentially expressed transcripts were identified and cloned. 
Sequence homology search revealed and matched the identified clones to 1) a small 
subset of genes known to be involved in angiogenesis, e.g. platelet endothelial cell adhe- 
sion molecule 1 (PECAM-I), matrix metalloproteinase 2 (MMP2), endothelin converting 
enzyme 1 (ECE-I), and vascular endothelial growth factor receptor 2 (VEGFR-2); 2) a 
large subset of known genes with known function, but not involved in angiogenesis to 
date; and 3) about 5-10% of the clones were novel genes with unknown function, such as 
a putative G-protein coupled receptor. Thus there are clusters of related gene products, 
differentially regulated and involved with cholinergic, proliferative and apoptotic action. 
cDNA rmcroarray analysis (-48,000 elements) validated our findings Conclwon: Nico- 
tme promotes angiogenesis through stimulation of angiogenic mechanisms partly 
through the cholinerglc pathway. Therapeutic modulation of nAChR may be useful in dls- 
orders of angiogenesis. 
9:45 a.m. 
804-3 Relation Between the C,,,T Transition in the 
Methylentetrahydrofolate Reductase Gene, Plasma 
Homocyst(e)ine and Folate Levels, and Coronary Artery 
Disease in the GENICA (Genetic and Environmental 
Factors in Coronary Atherosclerosis) Study 
Gian Paolo ROSSI, Maurizto Cesarl, Albert0 Burlina, Stefania Colonna, Mario Zanchetta, 
Gluseppe Maiollno, Pietro Maiolino, Achille Cesare Pessina, Clinica Medica 4, Padova, 
Italy, Cittadella, Italy 
Background: Hyperhomocyst(e)inemia has been implicated in atherosclerws and can 
be determined by multiple environmental and genetlc factors. However, the relationship 
of the plasma levels of homocyst(e)ine (Ho) and folate (F) with the C?“T methylentet- 
rahydrofolate reductase (MTHFR) gene polymorphism and coronary artery disease 
(CAD) has never been investigated in a large clinlcal dataset. Methods: In 964 consecu- 
tive patients (63iiO yrs. 74% men and 26% women) of the “GENICA” study, who under- 
went coronary anglography for suspected CAD, we measured HO and F by HPLC and a 
chemilummescence method, respectively. All were genotyped for the d”T MTHFR 
gene polymorphism by fluorescent PCR and melting curve analysis (LightCycls+). 
ResuI1s: We found a highly significant (p<O.OOOl) inverse relationship between Ho and 
F. A multivariate analysis identified serum creatinine, Cs”T MTHFR genotypes, F, left 
ventncular election fraction, age, and an interaction between Cs7’T MTHFR genotypes 
and F, as significant predictors of Ho (Re0.16, p<O.OOOl). When the effect of the T 
MTHFR allele was examined according to a recessive model, significantly (pcO.0001) 
higher Ho values were seen in TT (14.9eO.6 Mmol/l) than in CC+CT (12.0r0.3 pmolll) 
patients. At variance no signlflcant difference was seen between patients with (14.0r0.6 
umol/l) and wthout CAD (I 3.OtO.4 ~molll). x2 analysis showed that high Ho (z-15 pmol/l) 
were more common than expected in patients with history of previous myocardial infarc- 
tion (p=O.O03), peripheral vascular disease (p<O.OOl), vascular surgery (p<O.OOl) and 
chronic renal failure (p<O.OOl). No associations of the C?“T MTHFR polymorphism with 
such outcomes were seen. Conclusions: These results, in patients with angiographl- 
tally-assessed CAD, support the contentlon of Ho being determined by multiple factors, 
including the Cs”T transItion in the MTHFR gene. Furthermore, they indicate that hyper- 
homocyst(e)inemia. but not the C?“T MTHFR alleles, are associated with cardiovascu- 
lar outcomes albeit not with anglographically assessed CAD. 
IO:00 a.m. 
804-4 Endothelin-1 Induces Expression of Functional CD40 on 
Human Vascular Smooth Muscle Cells 
Michael Browatzki. Caroline A. Pfeiffer, Roger Kranzhbfer, University of Heidelberg, 
Heidelberg, Germany 
Background: Chronic inflammation of the vessel wall IS a hallmark of atherosclerosis. 
This inflammatory process is maintalned by a variety of cytokines generated in the vessel 
wall. Recently, activatmn of vascular cells by cell-cell contact via the CD40lCDl54 sys- 
tem has been identified as Important pathway of inflammatory stimulation in atherogene- 
sis. Human vascular smooth muscle cells @MC) as important cellular component of the 
atherosclerotic plaque can express both cytokines and the CD40/CDl54 system. On the 
other hand, the vasoactve peptide endothelin-1 (ET-l) is supposed to contribute to 
atherogenesis. This study investigated whether ET-l stimulates the inflammatory 
response in SMC via a CD40/CD154 dependent pathway. Methods and Results: ET-l 
(10 nM max) like the positive stimulus interieron-gamma (100 U/ml) increased CD40 
mRNA and protein expression after 24 hours in human SMC. This ET-l effect was medi- 
ated by the ET-A-receptor subtype since BQ-123, a selective ET-A receptor antagonist, 
prevented ET-l-induced CD40 upregulatlon whereas BQ-788. an ET-B-receptor antago- 
nist, did not (10 pM each). ET-l also activated the proinflammatory transcription factors 
NF-kappaB and AP-1 in a time dependent manner. The specific proteasome inhibitor PI- 
1 (50 PM) and a NF-kappaB decoy oligodesoxynucleotide prevented ET-l-induced CD40 
expression demonstrating dependence of this ET-1 effect on NF-kappa6 activation To 
test the functional relevance of the CD40 expression, SMC were premcubated with IO 
nM ET-1 for 24 hours and afterwards stimulated with recombinant CD154 (5 ng(ml). 
Release of Interleukin-6 (IL-6) into the culture medium was assessed by ELISA. Cells 
preincubated with ET-1 secreted a slgniflcantly higher amount of IL-6 under CD154 stim- 
ulation than control cells (265 +/- 4 vs 147 +/- 8 pglml, p < 0.05). Conclwon: ET-l 
induces an inflammatory response I” human SMC wa direct cell-cell contact which is 
medlated by the CD40ICD154 system. This mechanism may contribute to the pathogen- 
esis of atherosclerosis. 
10:15 a.m. 
804-5 Decreased Caveolin-l Expression in Atheroma: Loss of 
Antiproliferative Control of Vascular Smooth Muscle 
Cells in Human Atherosclerosis 
Carsten Schwencke, Alexander Schmeisser. Rolf Wachter, Brigina Week, Rainer 
Marquetant, Michael Kasper, Ruth H. Strasser, University of Technology Dresden, 
Dresden, Germany 
Background: Proliferation of vascular smooth muscle cells (VSMC) is involved in the 
pathogenws of primary atherosclerosis and restenosis after angioplasty. On the back- 
ground of the recently proposed antiproliferative actiwties of caveolm1 the present study 
investigated the expression of caveolin- in proliferating VSMC in vitro and especially in 
human atheroma. 
Methods and Results: Primary VSMC express high levels of caveolin- as shown by 
immunoblotting. Supplementation of serum or growth factors such as PDGF caused a 
decrease in caveolin- expressjon in VSMC. Cell-cycle entry was documented by a 
decrease of the Cdk inhibitor p27kipl and an increase of the proliferating cell nuclear 
antigen (PCNA). We further investigated the expression of caveolin- in VSMC of human 
atheroma using immunohistochem&y. In contrast to control vessels, caveolin- was 
markedly decreased in sections derived from human atheroma. The proliferation of 
VSMC m atheroma was confirmed by an increased PCNA immunostaining. 
Conclusion:Thls newly characterized decreased expression of caveolin- both in prolif- 
erating smooth muscle cells in vitro and in human atheroma in viva strongly links the loss 
of the antiproliferative control by caveolin- to the development of atherosclerosis, sug- 
gesting a pivotal role of caveolin- in the pathogenesis of atherosclerosis. 
ORAL CONTRIBUTIONS 
811 Pulmonary Hypertension and Pulmonary 
Embolism: Clinical Insights 
Monday, March 31, 2003, 11:OO a.m.-12:15 p.m. 
McCormick Place, Room S102 
1 l:oo a.m. 
811-1 Pulmonary Artery Systolic Pressure in 
Echocardiographically Normal Subjects 
Richard V Milani, Carl J. Lavie, Yvonne E. Gilliland. Krishnamoorthy Vivekananthan. 
Mark M. Cassidy, Jose Albert0 Bernal, Ali Morshedl, Ochsner Clinic Foundation, New 
Orleans, LA 
Backgrond: Pulmonary hypertension (PHTN) has undergone renewed interest of late 
with the increasing prevalence of obesity and the reported association of various anorec- 
tic agents and its subsequent effect on the pulmonary vasculature. Recent enhance- 
ments I” echocardiographic instrumentation, has refined the detection of small degrees 
of tricuspid regurgitation in subjects, and mild “elevations” of pulmonary artery systolic 
pressure (PASP) are now a common finding, resulting in concern as to whether this rep- 
resents true pathology. Previous definitions of PHTN suggested that PASP exceeding 30 
mmHg were pathologic, however this data was often derived from small numbers of rela- 
tively young patients. 
Methods: We have analyzed PASP from our echocardiographic database of 35,815 sub- 
jects, resulting in 2,472 subjects (mean age 54.9 +I- 16.3 years) which met the echo cri- 
teria of normal hearts, defined as: normal left and right ventricular dimension and 
function; normal left and right atrial dimensions; absence of aortic root dilatation or peri- 
cardial disease; absence of valvular stenosis; absence of valvular insufficiency less than 
moderate. 
Results: The mean PASP was 33.1 +/- 7.7 mmHg, and correlations were found wth age 
(p=O.OOOl), male gender (p=O.O025), septal wall thickness (p=O.OOOl) and posterior wall 
thickness (p=O.OOOl). 60% of this population had a PASP > BOmmHg, and 22% of those 
older than 50 years, and 20% of those with BMI > 30 kgIm2, had a PASP > 40mmHg. 
Conclusions: Elevations of PASP is relatively common in echocardiographically normal 
populations and correlate to age and BMI. Previous definitions of normal PASP should 
be revised to adjust for age. 
11:15 a.m. 
811-2 Inhibition of Phosphodiesterased and Nitric Oxide 
Similarly Reduce Pulmonary Artery Pressure at High 
Altitude 
Hans P. Brunner-La Rocca Patrick Egger, Oliver Senn, Manuel Ftschler, Rahel 
Thalmann, Konrad Bloch, Marco Magglorini, Unwersity Hospital, Zurich, Switzerland, 
Uwersity Hospital, Basel, Switzerland 
Background At high altitude, hypoxia induces pulmonary hypertension which plays an 
Important role in the pathophysiology of high-altitude pulmonary edema. Inhaled nitric 
oxide (NO) was shown to reduce pulmonary artery pressure (PAP), but it is not applica- 
ble in parctlce. Therefore, we investigated the effects of the PDEB-Inhibitor sildenafil (Sil) 
on PAP at high altitude in comparison with Inhaled NO. 
Methods Doppler-echocardiography was performed in 22 healthy mountaineers (10 W, 
12 M, age 29*12y; Q-saturation 75*3%) 3 hours after they reached an altitude of 
4559m. Measurements were repeated after NO (40ppm), Sil (50mg), and Sil plus NO. 
PAP was estimated from trtcuspid regurgitation and pulmonary vascular resistance 
